Abstract

Past studies with the live, double-mutant B. abortus (znBAZ) strain resulted in nearly complete protection of mice against pulmonary challenge with wild-type (wt) Brucella via a dominant CD8+ T cell response. To understand the contribution innate immune cells in priming CD8+ T cell responses, mice were nasally dosed with wt B. abortus, smooth vaccine strain 19 (S19), or znBAZ, and examined for innate immune cell activation. Flow cytometric analysis revealed that znBAZ, but not wt B. abortus nor S19 infection, induces up to a 5-fold increase in the frequency of IFN-γ-producing NK cells in mouse lungs. These NK cells express increased CXCR3 and Ki67, indicating their recruitment and proliferation subsequent to znBAZ infection. Their activation status was augmented noted by the increased NKp46 and granzyme B, but decreased NKG2A expression. Further analysis demonstrated that both lung caspase-1+ inflammatory monocytes and monocyte-derived macrophages secrete chemokines and cytokines responsible for NK cell recruitment and activation. Moreover, neutralizing IL-18, an NK cell-activating cytokine, reduced the znBAZ-induced early NK cell response. NK cell depletion also significantly impaired lung dendritic cell (DC) activation and migration to the lower respiratory lymph nodes (LRLNs). Both lung DC activation and migration to LRLNs were significantly impaired in NK cell-depleted or IFN-γ-/- mice, particularly the CD11b+ and monocytic DC subsets. Furthermore, znBAZ vaccination significantly induced CD8+ T cells, and upon in vivo NK cell depletion, CD8+ T cells were reduced 3-fold compared to isotype-treated mice. In summary, these data show that znBAZ induces lung IFN-γ+ NK cells, which plays a critical role in influencing lung DC activation, migration, and promoting protective CD8+ T cell development.

Highlights

  • Brucellosis is one of the most prevalent bacterial zoonotic diseases worldwide and listed by the World Health Organization as one of the “seven most neglected diseases” [1,2,3]

  • All animal experiments performed with live attenuated Brucella vaccine strains strain 19 (S19) and znBAZ were conducted under biosafety level-2 (BSL-2) containment; studies involving wt B. abortus 2308 were done under BSL-3 containment

  • Different doses were used since wt B. abortus 2308 and S19 are pathogenic in mice, whereas znBAZ is a highly attenuated strain [31] compared to these strains. znBAZ showed a modest increase in lung colonization by day 10, but afterwards declined by greater than two-logs by day 15 (Supplementary Figure 1A)

Read more

Summary

Introduction

Brucellosis is one of the most prevalent bacterial zoonotic diseases worldwide and listed by the World Health Organization as one of the “seven most neglected diseases” [1,2,3]. While commonly thought of as a disease of livestock, the four closely-related Brucella species – B. abortus, B. melitensis, B. suis, and B. canis - can cause human disease [4, 5]. Brucella is transmitted from infected animals to humans through direct contact, ingestion of contaminated foods, or by inhalation of Brucella-laden aerosols [6]. The most common routes of infection in humans are oral via consumption of contaminated foods or inhalation [15]. Induction of strong mucosal immunity in the aerodigestive tracts is desirable to provide efficient and long-lasting protection against Brucella infection. Given the routes of exposure, a mucosal vaccine that activates immunity in the lungs and gut seems a logical step to advancing Brucella vaccines. Mucosal vaccines may provide better coverage against pathogens than those given parenterally

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call